## 9. Summary of Safety and Effectiveness - "510 (k) Summary"

# A. Submitter Information

SOPRO ZAC Athélia Avenue des Genévriers 13705 La Ciotat Cedex FRANCE

Telephone: 33 (0) 442 98 01 01

Fax: 33 (0) 442 71 76 90

DEC 1 3 2007

Contact Person:

Steve Salesky

SOPRO

c/o ACTEON, Inc.

124 Gaither Drive, Suite 140

Mt. Laurel, NJ 08054 Tel: 800 289-6367 Ext. 40

Fax: 856 222-4726

E-mail: steve.salesky@us.acteongroup.com

Date Prepared:

March 13, 2007

#### B. Device Identification

Classification Name:

Laparoscopic Insufflator

Common Usual Name:

Laparoscopic CO<sub>2</sub> Insufflator

Proprietary Name:

SOPRO 640 laparoscopic Insufflator

# C. Identification of Predicate Device

<u>Device</u> HI-FLO THERME Applicant

510(k) No. K031014 Date Cleared June 27, 2003

PNEU 45, WISAP

**GESELLSCHAFT** 

#7083, 7083V FL

FUR

WISAP

WISSENSCHAFTL. APP. BAU MB

The SOPRO 640 laparoscopic Insufflator is substantially equivalent to the predicate device by WISAP GESELLSCHAFT FUR WISSENSCHAFTL. APP. BAU MB, the HI-FLO THERME PNEU 45, WISAP #7083, 7083V (K031014) previously cleared by the FDA and currently marketed.

### D. <u>Device Description</u>

The SOPRO 640 insufflator supplies CO<sub>2</sub> gas from cylinders to build up a pneumoperitoneum with CO<sub>2</sub> Gas for diagnostic or operative Laparoscopy with a maximum flow rate of 20, 30 or 45 liters per minute dependent on the model selected.

The insufflation pressure is user adjustable between 0 and 24 mmHg. The safety features include acoustic and visual alarms for overpressure and low gas supply.

#### E. Intended Use

The SOPRO 640 Laparoscopic Insufflator may only be used by qualified physicians for building up a pneumoperitoneum with CO<sub>2</sub> Gas for diagnostic or operative Laparoscopy.

#### F. Substantial Equivalence

The SOPRO 640 laparoscopic Insufflator and the predicate device by WISAP GESELLSCHAFT FUR WISSENSCHAFTL. APP. BAU MB, the HI-FLO THERME PNEU 45, WISAP #7083, 7083V (K031014) are both laparoscopic insufflators for use in diagnostic and/or operative laparoscopy by qualified physicians. Differences that exist between the devices relating to technical specifications, performances, and intended use are minor and do not affect the safety and effectiveness of the SOPRO 640 Laparoscopic Insufflator.



DEC 1 3 2007

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

SOPRO % Mr. Steven Salesky Quality Manager ACTEON North America, Inc. 124 Gaither Drive, Suite 140 MOUNT LAUREL NJ 08054

Re: K070783

Trade Name: SOPRO 640 Laparoscopic Insufflator

Regulation Number: 21 CFR 884.1730 Regulation Name: Laparoscopic insufflator

Product Code: HIF

Dated: November 28, 2007 Received: November 29, 2007

Dear Mr. Salesky:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the <u>Code of Federal Regulations</u>, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter.

21 CFR 876.xxxx	(Gastroenterology/Renal/Urology)	240-276-0115
21 CFR 884.xxxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 892.xxxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours,

Mancy C Brogdon
Nancy C. Brogdon

Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

# Indications for Use

510(k) Number:	K070783	<u>.                                    </u>		
Device Name:	SOPRO 640 Laparoscopic Ins	ufflator		
Indications for Use:				
The SOPRO 640 Lap for building up a pneu Laparoscopy.	aroscopic Insufflator may only be moperitoneum with CO₂ Gas for	e used by qualified physicians diagnostic or operative		
Prescription Use		Over-The-Counter Use(21 CFR 801 Subpart C) NTINUE ON ANOTHER PAGE		
Concurrence of CDRH, Office of Device Evaluation (ODE)				